The results showed that in advanced NSCLC patients harboring EGFR-sensitive mutations, first-line TKI therapy was superior to platinum-based chemotherapy in both ORR and PFS, which is consistent with the available data [23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.